Two River and Vida Ventures Extend Track Record of Company Creation and Value Realization Following the Candid Therapeutics’ Acquisition by UCB
LOS ANGELES, BOSTON & NEW YORK–(BUSINESS WIRE)–Two River, LLC (“Two River”) and Vida Ventures (“Vida”), both part of the Bellco Health ecosystem, today acknowledged the announced acquisition of Candid Therapeutics (“Candid”), a privately held clinical-stage biotechnology company redefining the treatment of autoimmune and inflammatory diseases through novel T-cell engagers (TCEs), by UCB (Euronext: UCB), a … [Read more…]
